Re:Search Institution Members

157 Results for Members

Members

The Alexandria University is a public research university in Alexandria, Egypt.

Merck KGaA is a pharmaceutical and life sciences company and a funding member of WIPO Re:Search. The company...

Murdoch Children's Research Institute (MCRI) specializes in research to prevent and treat childhood conditions...

The National Center for Genetic Engineering and Biotechnology (BIOTEC) functions as a research institute, with...

The National Institute of Industrial Property (INPI) is the official government body responsible for...

Operation ASHA is dedicated to bringing tuberculosis treatment and health services to the poorest of the poor...

166 Results for Collaborations

Collaborations

MSD provided an Emory University researcher studying tuberculosis with membrane-bound protein purification expertise.

MSD will provide a UCSF/UCSD researcher with HMG-CoA reductase inhibitors (statins) to screen against schistosomal worms. CIDR will attempt to solve the structure of the S. mansoni HMG-CoA reductase.

MSD will provide a WEHI researcher with a targeted set of compounds to screen against Plasmodium.

The NIH will provide IDRI researchers with natural product extracts to screen against M. tuberculosis.

The NCI/NIH provided IDRI researchers with natural products to test against kinetoplastids.

Researchers from IP Tunis will be utilizing the NIAID/NIH pre-clinical services program to increase thermostability of IP Tunis’ investigational rabies vaccine.

170 Results for Assets

Assets

Growing evidence suggests that the presence of a subpopulation of hypoxic non-replicating phenotypically drug resistant mycobacteria is responsible for lengthy tuberculosis treatment. The respiratory functions were demonstrated to represent the Achille's heel of hypoxic non-replicating Mycobacterium tuberculosis. Here, we describe the development of a hypoxic model optimized to identify compounds targeting the mycobacterial respiratory functions and ATP homeostasis in a whole-cell screen. The model was adapted to the 1536-well plate format and successfully used to screen over 600,000 compounds. 900 compounds were confirmed to reduce intracellular ATP levels in a dose-dependant manner. 155 non-cytotoxic scaffolds with anaerobic activity against hypoxic non-replicating M. tuberculosis were identified. This collection of disruptors of ATP homeostasis represents a valuable tool to decipher the biology of persistent mycobacteria.
5 series, Total of 371 exemplified compounds, Pending patent applications
Nucleic acid, recombinant vector, host cells, expression systems, 289 compounds, exemplified in 1 series, 2 granted patents and pending patent applications.
TRC is looking to develop partnerships with interested parties wishing to gain access to its comprehensive parasite bank, for the purposes of genetic sequencing and / or the development of new diagnostic tools and vaccines. The bank contains all human trypanosomes, all animal infective parasites, DNA from vectors of Trypanosomiasis.
TRC is looking for partners interested in working towards the commercialization of its Infectra-kit, an acrylic mouse restraint device for vector infection studies. The device allows essential transmission studies to be carried out with minimal human manipulation and without the need for anaesthesia. Infectra®-kit can be used as a single unit for restraining one mouse or as eight-assembled units, thus significantly improving efficiency of a single operator in comparison to manual restraint. The device has been validated for use in Trypanosomiasis research, and is undergoing validation for use in malaria research. • Has a single-fly holding cage and en mass fly holding cage. • Interaction of mouse with vector is facilitated through wire mesh fitted on the restrainer. • Allows for ventral or dorsal inoculation of the mouse. • Authors verified its use by comparing tsetse fly feeding rates on mice in the Infectra®-Kit vs. manual hand-holding.
TRC maintains significant animal testing facilities, including the capacity to hold up to 150 primates. TRC is looking to enter into collaborative partnerships, including contract research, for organizations wishing to undertake in vivo pre-clinical studies into the safety and toxicity of drug candidates and diagnostic tools, using its primate model.